USD
( +0.00%
At Close (As of Jan 1, 1970)
$34.38M
Market Cap
-
P/E Ratio
-0.23
EPS
$0.94
52 Week High
$0.27
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $1.2M |
| Total Revenue | $1.2M |
| Cost Of Revenue | $1.3M |
| Costof Goods And Services Sold | $1.3M |
| Operating Income | -$27M |
| Selling General And Administrative | $13M |
| Research And Development | $14M |
| Operating Expenses | $28M |
| Investment Income Net | - |
| Net Interest Income | -$330K |
| Interest Income | $9.9K |
| Interest Expense | $340K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $1.3M |
| Income Before Tax | -$27M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$27M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$27M |
| Ebitda | -$26M |
| Net Income | -$27M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $1.2M |
| Total Revenue | $1.2M |
| Cost Of Revenue | $1.3M |
| Costof Goods And Services Sold | $1.3M |
| Operating Income | -$27M |
| Selling General And Administrative | $13M |
| Research And Development | $14M |
| Operating Expenses | $28M |
| Investment Income Net | - |
| Net Interest Income | -$330K |
| Interest Income | $9.9K |
| Interest Expense | $340K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $1.3M |
| Income Before Tax | -$27M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$27M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$27M |
| Ebitda | -$26M |
| Net Income | -$27M |
Sector: HEALTHCARE
Industry: MEDICAL DEVICES
VolitionRx Limited (VNRX) is an innovative multinational epigenetics company based in Austin, Texas, dedicated to developing blood-based diagnostic tests aimed at improving cancer detection and other disease diagnoses globally. Utilizing its proprietary Nu.Q™ platform, VolitionRx focuses on creating advanced, non-invasive diagnostic solutions that seek to enhance patient outcomes through early disease detection. Positioned at the cutting edge of the expanding epigenetics market, the company is strategically positioned to address the increasing demand for accurate and reliable diagnostic tools in oncology and beyond, signaling significant growth potential.